Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2018 Q2- Text added to 2018 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
abbreviated, antibody, biosimilar, carefully, Cloud, crizanlizumab, deposit, diagnostic, driven, Easement, entail, Expedient, Goodwill, hosting, inclacumab, interchangeable, mid, modification, monoclonal, monthly, perpetual, prepayment, relocate, rentable, repaid, repay, Roche, royalty, sixty, software, sublicensable, Substitute, surrender, tier, tiered, upfront, vacate, VOC
Valuein 2018 Q2 filing- Value in 2018 Q3 filing
Original filings
Filing view